Generalized eruptive histiocytosis

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:157991D76.3
Who is this for?
Show terms as
8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Generalized eruptive histiocytosis (GEH) is a rare non-Langerhans cell histiocytosis characterized by the widespread eruption of small, firm, red-brown to skin-colored papules distributed symmetrically over the face, trunk, and proximal extremities. The condition results from a benign proliferation of histiocytes (tissue macrophages) in the skin. GEH primarily affects the integumentary system (skin), though mucosal involvement has occasionally been reported. The papules are typically asymptomatic or mildly pruritic, measuring 2–10 mm in diameter, and tend to appear in successive crops. Histologically, the lesions show a dermal infiltrate of mononuclear histiocytes without lipidization, Touton giant cells, or significant inflammatory infiltrate. Immunohistochemistry is positive for CD68 and negative for CD1a and S-100, distinguishing it from Langerhans cell histiocytosis. GEH is generally considered a benign and self-limiting condition, with lesions often resolving spontaneously over months to years, sometimes leaving hyperpigmented macules or slight atrophy. However, some cases have been reported to progress to or be associated with other forms of non-Langerhans cell histiocytosis, such as xanthoma disseminatum or progressive nodular histiocytosis, suggesting that GEH may represent an early or transitional phase within a spectrum of histiocytic disorders. Rarely, GEH has been reported in association with hematologic malignancies. There is no established standard treatment for generalized eruptive histiocytosis given its typically self-resolving nature. Management is generally expectant with clinical monitoring. In cases where lesions are persistent, cosmetically bothersome, or symptomatic, treatments that have been tried with variable success include topical or systemic corticosteroids, isotretinoin, PUVA phototherapy, and dapsone. Patients require follow-up to monitor for potential progression to other histiocytic disorders or development of associated systemic conditions.

Also known as:

Clinical phenotype terms— hover any for plain English:

Erythematous maculeHP:0025475HistiocytosisHP:0100727Maculopapular exanthemaHP:0040186Elevated total serum tryptaseHP:0031901Severely increased total eosinophil countHP:0032061Abnormal circulating vitamin B12 concentrationHP:0040126LeukemiaHP:0001909Spotty hyperpigmentationHP:0005585Abnormal Langerhans cell morphologyHP:0031871
Inheritance

Sporadic

Usually appears on its own, not inherited from a parent

Age of Onset

Adult

Begins in adulthood (age 18 or older)

Orphanet ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Generalized eruptive histiocytosis.

View clinical trials →

No actively recruiting trials found for Generalized eruptive histiocytosis at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Generalized eruptive histiocytosis community →

No specialists are currently listed for Generalized eruptive histiocytosis.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Generalized eruptive histiocytosis.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Generalized eruptive histiocytosisForum →

No community posts yet. Be the first to share your experience with Generalized eruptive histiocytosis.

Start the conversation →

Latest news about Generalized eruptive histiocytosis

No recent news articles for Generalized eruptive histiocytosis.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Generalized eruptive histiocytosis

What is Generalized eruptive histiocytosis?

Generalized eruptive histiocytosis (GEH) is a rare non-Langerhans cell histiocytosis characterized by the widespread eruption of small, firm, red-brown to skin-colored papules distributed symmetrically over the face, trunk, and proximal extremities. The condition results from a benign proliferation of histiocytes (tissue macrophages) in the skin. GEH primarily affects the integumentary system (skin), though mucosal involvement has occasionally been reported. The papules are typically asymptomatic or mildly pruritic, measuring 2–10 mm in diameter, and tend to appear in successive crops. Histolo

How is Generalized eruptive histiocytosis inherited?

Generalized eruptive histiocytosis follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Generalized eruptive histiocytosis typically begin?

Typical onset of Generalized eruptive histiocytosis is adult. Age of onset can vary across affected individuals.